NPPA seeks clarification on Gilead's drug pricing plea

National Pharmaceutical Pricing Authority has sought clarifications
from the company. Gilead had sought exemption from price control for
its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a
major chunk of Rs 140-crore market for chronic Hepatitis B in India.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-seeks-clarification-on-gileads-drug-pricing-plea/articleshow/73788094.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment